First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
Ansell, S. M. Connors, J. M. Kim, W. S. Gallamini, A. Ramchandren, R. Friedberg, J. W. Advani, R. H. Hutchings, M. Evens, A. M.
Ansell, S. M.
Connors, J. M.
Kim, W. S.
Gallamini, A.
Ramchandren, R.
Friedberg, J. W.
Advani, R. H.
Hutchings, M.
Evens, A. M.
Citations
Altmetric:
Abstract
Authors
Ansell, S. M.
Connors, J. M.
Radford, John A
Kim, W. S.
Gallamini, A.
Ramchandren, R.
Friedberg, J. W.
Advani, R. H.
Hutchings, M.
Evens, A. M.
Smolewski, P.
Savage, K. J.
Bartlett, N. L.
Eom, H. S.
Abramson, J. S.
Dong, C.
Campana, F.
Fenton, K.
Puhlmann, M.
Straus, D. J.
Connors, J. M.
Radford, John A
Kim, W. S.
Gallamini, A.
Ramchandren, R.
Friedberg, J. W.
Advani, R. H.
Hutchings, M.
Evens, A. M.
Smolewski, P.
Savage, K. J.
Bartlett, N. L.
Eom, H. S.
Abramson, J. S.
Dong, C.
Campana, F.
Fenton, K.
Puhlmann, M.
Straus, D. J.
Affiliation
Mayo Clinic, Rochester, MN
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Ansell SM, Connors JM, Radford JA, Kim WS, Gallamini A, Ramchandren R, et al. First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301966.